Anturec Pharmaceuticals is a German anticancer drug development company which was founded in 2020 based on research carried out at University Hospital Muenster. The company’s target is aminopeptidase N (CD13) located on cells of the tumor vasculature and some tumor cells, but absent from most mature blood vessels. The company’s founders have designed and studied […]

View post to subscribe to site newsletter.

Founded in 2020, Signet Therapeutics is developing targeted small molecule cancer drugs using novel disease models. Dr. Haisheng Zhang, CEO of Signet Therapeutics, and his core team members originate from Dana-Farber Cancer Institute, Harvard Medical School. The company says that traditional in vitro studies use cell lines that cannot accurately model patient’s drug performance, often […]

View post to subscribe to site newsletter.

Quris is developing a fully automated, self-training AI platform designed to better predict clinical safety and efficacy for new drug candidates. The company is pioneering clinical trials on chips, which involves testing thousands of novel drug candidates on hundreds of stem-cells-derived “patients-on-a-chip”. Its fully automated, self-training AI platform is designed to accurately predict clinical safety […]

View post to subscribe to site newsletter.